Interim Report January – September 2020
ChromoGenics conducts a preferential share issue for accelerated growth
ChromoGenics conducts a preferential share issue for accelerated growth
ChromoGenics adopts a position for accelerated growth
The annual general meeting in ChromoGenics AB (publ), org.nr 556630-1809 (the ”Company”) was held on 14 May 2020 at the…
ChromoGenics completed a preferential share issue for SEK 76.2 million to accelerate growth
The shareholders in ChromoGenics AB (publ), reg. no. 556630-1809 (the “Company”) are hereby convened to the annual general meeting on…
ChromoGenics increases its business volume and completes preferential share issue for SEK 100.6 million, guaranteed to 75 percent, for accelerated…
The Board of Directors of ChromoGenics AB (”ChromoGenics” or ”the Company”) has today, pursuant to the authorization granted by the…
An extraordinary general meeting in ChromoGenics AB (publ) was held on 18 December 2019 at the company’s premises on Söderforsgatan…
ChromoGenics acquires own sputtering capacity and strengthens the company’s strategy to have stable and quality-assured production of sputtered film for…
The shareholders in ChromoGenics AB (publ) corp. reg. no 556630‑1809 (the “Company”) are hereby convened to an extraordinary general meeting…
The Switch2save project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement…
As communicated in the Q2 report, ChromoGenics has had major quality problems from a supplier of sputtered film intended…
Privacy Overview